Immunomedics (IMMU) PT Raised to $31 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IMMU Hot Sheet
Price: $87.86 --0%
Rating Summary:
13 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
13 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi raised the price target on Immunomedics (NASDAQ: IMMU) to $31.00 (from $23.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Goldman Sachs upgrades Sirius XM Radio to Buy with $37 target
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
- Capri Holdings (CPRI) PT Raised to $19 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
